UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 103

Sortiert nach

Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study

International journal of cardiology, 2022-01, Vol.346, p.93-99

2022

Volltextzugriff (PDF)

Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study

BMC cardiovascular disorders, 2020-12, Vol.20 (1), p.504-10, Article 504

2020

Volltextzugriff (PDF)

Correction to: Elderly patients with atrial fibrillation in routine clinical practice: peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study

BMC cardiovascular disorders, 2021-02, Vol.21 (1), p.91-1, Article 91

2021

Volltextzugriff (PDF)

Acute effects of cigarette smoking on pulmonary function

Regulatory toxicology and pharmacology, 2010-07, Vol.57 (2-3), p.241-246

2010

Volltextzugriff (PDF)

Two-year effectiveness and safety outcomes in 27,333 edoxaban-treated patients with and without a history of major bleeding from the Global ETNA-AF programme

European heart journal, 2022-10, Vol.43 (Supplement_2)

2022

Volltextzugriff (PDF)

Baseline demographic and clinical characteristics as predictors of adverse outcomes to improve management of patients with AF receiving edoxaban: a subanalysis of the ETNA-AF registry

European heart journal, 2023-11, Vol.44 (Supplement_2)

2023

Volltextzugriff (PDF)

Clinical outcomes in patients receiving oral anticoagulation stratified by the presence of dose reduction criteria and older age: a subanalysis of ENVISAGE-TAVI AF

European heart journal, 2023-11, Vol.44 (Supplement_2)

2023

Volltextzugriff (PDF)

Persistence to edoxaban treatment in patients with atrial fibrillation: Analysis from the Global ETNA-AF program

European heart journal, 2023-11, Vol.44 (Supplement_2)

2023

Volltextzugriff (PDF)

Comparison of clinical outcomes with edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonist in patients with atrial fibrillation in Germany: a real-world cohort study

European heart journal, 2020-11, Vol.41 (Supplement_2)

2020

Volltextzugriff (PDF)

Effectiveness and safety of edoxaban in atrial fibrillation patients from the ETNA-AF global registry

European heart journal, 2021-10, Vol.42 (Supplement_1)

2021

Volltextzugriff (PDF)

Management of edoxaban therapy in patients undergoing emergency/urgent procedures: a subanalysis of the global, prospective, observational, multinational EMIT-AF/VTE programme

Europace (London, England), 2024-05, Vol.26 (Supplement_1)

2024

Volltextzugriff (PDF)

The real-world effectiveness and safety of edoxaban treatment in 27,333 Global ETNA-AF programme patients with and without a history of heart failure

European heart journal, 2022-10, Vol.43 (Supplement_2)

2022

Volltextzugriff (PDF)

Real-world effectiveness and safety of edoxaban in patients with and without a history of ischaemic stroke: results from the ETNA-AF programme

European heart journal, 2022-10, Vol.43 (Supplement_2)

2022

Volltextzugriff (PDF)

Decoding definitions of major bleeding in retrospective observational studies on direct oral anticoagulants for atrial fibrillation: a targeted literature review

Europace (London, England), 2024-05, Vol.26 (Supplement_1)

2024

Volltextzugriff (PDF)

Edoxaban treatment of elderly patients with atrial fibrillation in routine clinical practice: 1-year results of the non-interventional Global ETNA-AF program

European heart journal, 2020-11, Vol.41 (Supplement_2)

2020

Volltextzugriff (PDF)

Management of edoxaban in patients undergoing multiple procedures: a subanalysis of the EMIT-AF/VTE program

Europace (London, England), 2022-05, Vol.24 (Supplement_1)

2022

Volltextzugriff (PDF)

One-year effectiveness and safety outcomes of edoxaban treatment in Chinese patients with atrial fibrillation: First snapshot of more than 4,800 patients from the ETNA-AF-China study

Europace (London, England), 2024-05, Vol.26 (Supplement_1)

2024

Volltextzugriff (PDF)

Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial

The Lancet (British edition), 2009-11, Vol.374 (9704), p.1840-1848

2009

Volltextzugriff (PDF)

Periprocedural management of patients on edoxaban undergoing pacemaker and cardiac monitoring device implantation - a sub-analysis of the EMIT-AF/VTE study

Europace (London, England), 2021-05, Vol.23 (Supplement_3)

2021

Volltextzugriff (PDF)

Periprocedural anticoagulation management in edxoaban patients undergoing catheter-based cardiovascular procedures: analyses of the noninterventional global EMIT study

Europace (London, England), 2021-05, Vol.23 (Supplement_3)

2021

Volltextzugriff (PDF)

Effectiveness and safety of edoxaban in 27,333 patients from ETNA-AF with and without a history of intracranial haemorrhage after 2 years of treatment

Europace (London, England), 2022-05, Vol.24 (Supplement_1)

2022

Volltextzugriff (PDF)

Baseline characteristics of edoxaban treatment in routine clinical practice for patients with non-valvular atrial fibrillation in China (ETNA-AF-China)

Europace (London, England), 2023-05, Vol.25 (Supplement_1)

2023

Volltextzugriff (PDF)

Temporal trend of clinical events in patients with atrial fibrillation on edoxaban therapy: results from the non-interventional global ETNA-AF program

European heart journal, 2021-10, Vol.42 (Supplement_1)

2021

Volltextzugriff (PDF)

Edoxaban treatment in real-world practice is highly concordant with ESC atrial fibrillation guidelines: results from the non-interventional global ETNA-AF program

European heart journal, 2021-10, Vol.42 (Supplement_1)

2021

Volltextzugriff (PDF)

A Polyhydroxybutyrate biodegradable stent: Preliminary experience in the rabbit

Cardiovascular and interventional radiology, 2002-03, Vol.25 (2), p.127-132

2002

Volltextzugriff (PDF)

1 – 25 von 103

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(95)
Mit Volltextzugriff
(90)

Publikationsform

Artikel
(100)
Tagungsberichte
(3)

Sprache

Englisch
(83)
Deutsch
(21)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study

Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study

Acute effects of cigarette smoking on pulmonary function

Two-year effectiveness and safety outcomes in 27,333 edoxaban-treated patients with and without a history of major bleeding from the Global ETNA-AF programme

Baseline demographic and clinical characteristics as predictors of adverse outcomes to improve management of patients with AF receiving edoxaban: a subanalysis of the ETNA-AF registry

Clinical outcomes in patients receiving oral anticoagulation stratified by the presence of dose reduction criteria and older age: a subanalysis of ENVISAGE-TAVI AF

Persistence to edoxaban treatment in patients with atrial fibrillation: Analysis from the Global ETNA-AF program

Comparison of clinical outcomes with edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonist in patients with atrial fibrillation in Germany: a real-world cohort study

Effectiveness and safety of edoxaban in atrial fibrillation patients from the ETNA-AF global registry

Management of edoxaban therapy in patients undergoing emergency/urgent procedures: a subanalysis of the global, prospective, observational, multinational EMIT-AF/VTE programme

The real-world effectiveness and safety of edoxaban treatment in 27,333 Global ETNA-AF programme patients with and without a history of heart failure

Real-world effectiveness and safety of edoxaban in patients with and without a history of ischaemic stroke: results from the ETNA-AF programme

Decoding definitions of major bleeding in retrospective observational studies on direct oral anticoagulants for atrial fibrillation: a targeted literature review

Edoxaban treatment of elderly patients with atrial fibrillation in routine clinical practice: 1-year results of the non-interventional Global ETNA-AF program

Management of edoxaban in patients undergoing multiple procedures: a subanalysis of the EMIT-AF/VTE program

One-year effectiveness and safety outcomes of edoxaban treatment in Chinese patients with atrial fibrillation: First snapshot of more than 4,800 patients from the ETNA-AF-China study

Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial

Periprocedural management of patients on edoxaban undergoing pacemaker and cardiac monitoring device implantation - a sub-analysis of the EMIT-AF/VTE study

Periprocedural anticoagulation management in edxoaban patients undergoing catheter-based cardiovascular procedures: analyses of the noninterventional global EMIT study

Effectiveness and safety of edoxaban in 27,333 patients from ETNA-AF with and without a history of intracranial haemorrhage after 2 years of treatment

Baseline characteristics of edoxaban treatment in routine clinical practice for patients with non-valvular atrial fibrillation in China (ETNA-AF-China)

Temporal trend of clinical events in patients with atrial fibrillation on edoxaban therapy: results from the non-interventional global ETNA-AF program

Edoxaban treatment in real-world practice is highly concordant with ESC atrial fibrillation guidelines: results from the non-interventional global ETNA-AF program

A Polyhydroxybutyrate biodegradable stent: Preliminary experience in the rabbit

Suchergebnisse filtern